Adaptimmune to sell cell therapy assets, including Tecelra, and lay off more staff

Adaptimmune is selling three cell therapy assets, including its sarcoma therapy Tecelra, to US WorldMeds for $55 million in cash after announcing plans earlier this year to further cut costs and seek “strategic options.” ...